Arcutis Completes Enrollment In Infant Atopic Dermatitis Trial Of ZORYVE Cream; Data Due In Q1, 2026

Arcutis Biotherapeutics (ARQT) has completed enrollment for its INTEGUMENT-INFANT Phase 2 trial evaluating ZORYVE cream 0.05% for mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months, with topline data anticipated in Q1 2026. This study seeks to expand the market for ZORYVE, a leading topical PDE4 inhibitor already FDA-approved in October 2025 for children aged 2-5 years, into a younger pediatric demographic. Following a 2.52% decline yesterday, ARQT shares saw a 2.84% increase in overnight trading, reflecting investor interest in this development.

Analysis

Arcutis Biotherapeutics (ARQT) has successfully completed enrollment for its INTEGUMENT-INFANT Phase 2 trial, evaluating ZORYVE cream 0.05% for mild to moderate atopic dermatitis in infants aged 3 to 24 months. This marks a critical step towards potentially expanding ZORYVE's market, as atopic dermatitis affects nearly 9.6 million U.S. children, with a significant 60% developing symptoms in their first year of life. ZORYVE is already FDA-approved for children aged 2-5 years, making this trial a key strategic move to address a younger, underserved patient population.

ZORYVE is a leading topical PDE4 inhibitor, offering a steroid-free treatment alternative for skin inflammation. The open-label, multicenter Phase 2 study enrolled 101 infants, primarily focusing on assessing the safety and tolerability of the cream over a four-week period. Successful data could significantly broaden the drug's label and enhance its competitive positioning in the pediatric dermatology market.

Topline data from the INTEGUMENT-INFANT study is anticipated in Q1 2026, serving as a significant future catalyst for ARQT. Despite a 2.52% decline in the stock during yesterday's trading, ARQT shares reacted positively to the news, rising 2.84% to $23.51 in overnight trading. This immediate market response indicates investor optimism regarding the potential for ZORYVE's expanded market reach and future revenue growth.

Key Decisions for Investors

• Investors should closely monitor the Q1 2026 topline data release for the INTEGUMENT-INFANT study, as positive safety and tolerability results could significantly expand ZORYVE's addressable market and valuation.
• Evaluate ARQT's current market capitalization and growth prospects, considering the potential for ZORYVE to become a leading treatment across a broader pediatric age range for atopic dermatitis.
• Assess the competitive landscape for infant atopic dermatitis treatments, noting ZORYVE's steroid-free profile as a potential key differentiator in this sensitive patient population.